Survodutide
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Mechanism of Action
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
Key Benefits
- Superior weight loss vs monotherapy (14.9% at 46 weeks)
- Once-weekly convenient dosing
- Proven efficacy in obesity, MASH, and Type 2 diabetes
- 62% MASH improvement in clinical trials
29-amino acid peptide Complex or non-standard sequence format
Weight Loss
- Obesity Without Diabetes
14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
- Obesity With Type 2 Diabetes
Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
- Sustained Weight Management
Dual mechanism addresses both energy intake and expenditure.
Metabolic
- MASH Treatment
62% achieved MASH improvement without fibrosis worsening at 4.8mg.
- Liver Fat Reduction
63-67% achieved ≥30% liver fat reduction.
- Type 2 Diabetes Control
HbA1c reduction up to -1.6% at highest doses.
Subcutaneous injection to abdomen (2+ inches from navel), upper thigh, or upper arm. Any time of day, with or without food.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Obesity - Conservative Start | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | SubQ |
| Obesity - Standard Protocol | 3.6-6.0mg | Once weekly | SubQ |
| MASH Treatment | 2.4-4.8mg | Once weekly | SubQ |
| Type 2 Diabetes | 0.3-2.7mg | Once weekly | SubQ |
Reconstitution Instructions
- Survodutide lyophilized powder vial
- Bacteriostatic water (1-2mL)
- Insulin syringe (29-31 gauge)
- Alcohol swabs
- 1 Remove vial from refrigerator; allow 15-30 minutes to reach room temperature
- 2 Clean rubber stoppers with alcohol swabs
- 3 Draw prescribed amount of bacteriostatic water
- 4 Insert needle at 45-degree angle into vial
- 5 Inject BAC water down vial side slowly to minimize foaming
- 6 Gently swirl (do not shake vigorously)
- 7 Allow 2-3 minutes for complete dissolution
- 8 Solution should be clear to slightly opalescent without particles
- 9 Store reconstituted solution in refrigerator immediately
Both GLP-1 agonists; combining risks excessive activation and GI side effects.
Demonstrated together in Phase 2 diabetes trials.
No known interactions; allowed in Phase 3 with monitoring.
Hypoglycemia risk; consider dose reduction.
May require insulin dose reduction due to improved glycemic control.
Take 1+ hour before survodutide due to delayed gastric emptying.
Risk of excessive glucagon receptor activation.
Possible nausea, reduced appetite (most common during escalation)
Initial weight loss begins; improved satiety between meals
Progressive weight loss; potential energy level improvements
Approaching steady-state; more consistent effects
Sustained weight loss; average 15-19% by week 46
Common Side Effects
- Nausea (40-66%)
- Diarrhea (25-49%)
- Vomiting (15-41%)
- Slight heart rate increase (mean 2-5 bpm)
Stop Signs - Discontinue if:
- Severe persistent nausea/vomiting preventing oral intake
- Signs of pancreatitis (severe abdominal pain radiating to back)
- Allergic reactions (rash, itching, difficulty breathing)
- Severe hypoglycemia with insulin/sulfonylureas
- Gallbladder symptoms (right upper quadrant pain)
- Significant tachycardia or arrhythmias
Contraindications
- Not recommended in pregnancy or breastfeeding
- Use contraception during treatment
Good Signs
- Clear to slightly opalescent solution without visible particles
- Sealed vial with intact rubber stopper
- Within expiration date
Warning Signs
- Slight foam after reconstitution is normal if disappears within minutes
Bad Signs
- Cloudy solution or visible particles indicates contamination
- Discoloration of powder or solution
- Phase 2 Obesity Trial Without Diabetes(2024)
387 participants; BMI ≥27 kg/m²; 46 weeks. 14.9% mean weight loss at 4.8mg; 83% achieved ≥5%, 69% achieved ≥10%, 55% achieved ≥15%.
- Phase 2 MASH and Fibrosis Trial(2024)
293 participants with biopsy-confirmed MASH; 48 weeks. MASH improvement: 62% (4.8mg) vs 14% placebo; 63-67% achieved ≥30% liver fat reduction.
- Phase 2 Type 2 Diabetes Trial(2023)
Head-to-head vs semaglutide 1.0mg; 16 weeks. Survodutide -8.7% weight loss vs semaglutide -5.3%; HbA1c reduction up to -1.6%.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.